Navigation Links
AIDS Foundation Lauds Brazil for Negotiating Price Cut on Abbott's Kaletra

AIDS Healthcare Foundation (AHF), the US' largest HIV/AIDS healthcare, prevention and education provider, which operates free AIDS treatment clinics in the US, Africa, Latin America/Caribbean and Asia, today lauded the government of Brazil for successfully negotiating a price cut of 30% on Abbott Laboratories' lifesaving medication, Kaletra (its two drug AIDS drug combination including lopinavir and ritonavir).

According to Bloomberg News Service, Brazil has pressed for discount prices on AIDS drugs to limit the cost of its program providing free treatment to all 200,000 people infected with AIDS and the HIV virus. The agreement extends to Brazil the same price structure Abbott has offered 44 other countries considered low and low-middle income, and it replaces a deal signed in 2005 when it lowered the price of the previous version of Kaletra by 46 percent in Brazil after the government threatened to break its patent.

"We commend the Government of Brazil for successfully negotiating this additional and significant price cut on a more patient-friendly version of Abbott's AIDS combination treatment, Kaletra," said Michael Weinstein, AIDS Healthcare Foundation's President. "However, this 30% price reduction on top of Brazil's previously-negotiated 46% price discount underscores to anyone who understands the most basic of mathematics just how random and arbitrary AIDS drug pricing by multi-national drug companies can be. Abbott has been the pharmaceutical industry's poster child for bad behavior of late -- they've blacklisted Thailand from any of its new drugs, sued the advocacy group, ACT Up Paris, and run rampant over a number of other recent drug access issues put forth by a number of advocacy groups. A 76% reduction on this lifesaving combination may seem significant for Brazil, but we still believe Abbott -- like most pharmaceutical companies -- can do far, far more to improve pricing and access to their lifesaving AIDS drugs around t he world." According to Bloomberg, "Kaletra is a protease inhibitor that blocks an enzyme involved in the virus's replication, slowing its progression to AIDS.

It's often used in combination with other drugs. It's the second most-used drug on Brazil's AIDS cocktail. About 31,000 adults and 1,200 children ingest it daily in Brazil."


'"/>




Related medicine news :

1. Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program
2. Kalam To Lay Foundation Of Vellore Research Center
3. Nippon Foundation To Help Leprosy Patients
4. Parents Launch SV40 Cancer Foundation In Memory of Son
5. Cancer Aid And Research Foundation: Offering Endless Hope To Cancer Patients
6. PM Launches Healthcare Foundation For India
7. Prime Minister Manmohan Singh, Flags Off Public Health Foundation of India
8. Gates Foundation to donate USD 104 million to TB Alliance
9. MoU for HIV/AIDS Signed by Nigeria and Clinton Foundation
10. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
11. Gates Foundation Adopts Fight against Encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi ... patients who do not do their research and undergo cosmetic dermatology treatments from unqualified ... midst of a renaissance and every other month a new treatment or device is ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted its first Swirl: A Wine Tasting Event in New York City, with ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... December 5, 2016 PharmaBoardroom today releases its new ... ... This report offers companies, investors, policymakers, and stakeholders crucial insight into ... Europe , home to some of the world,s most important ... in Novartis and Roche, and with a number one ranking globally in ...
(Date:12/4/2016)... CAMBRIDGE, Mass. , Dec. 4, 2016 /PRNewswire/ ... a leader in discovering and developing targeted kinase ... announced data from its ongoing Phase 1 trial ... of patients with advanced systemic mastocytosis (SM). Blueprint ... selective inhibitor of D816V mutant KIT. Approximately 90 ...
(Date:12/4/2016)... Dec. 3, 2016 Sickle cell disease (SCD) ... red blood cells that get stuck in veins and ... organ failure, and complications leading to death. Each year, ... SCD, and most of them lack access to comprehensive ... established long-term therapy for SCD, a pill called hydroxyurea ...
Breaking Medicine Technology: